Hansa Biopharma AB
OTC:HNSBF
Hansa Biopharma AB
OTC:HNSBF
Price:
2.9
USD
Market Cap:
$316.6m
Balance Sheet
Balance Sheet Decomposition
Hansa Biopharma AB
Hansa Biopharma AB
Balance Sheet Decomposition is not available for
Hansa Biopharma AB
Hansa Biopharma AB
Balance Sheet
Hansa Biopharma AB
Hansa Biopharma AB
Currency: SEK
| Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash & Cash Equivalents |
31
|
6
|
1
|
0
|
1
|
19
|
0
|
591
|
176
|
214
|
581
|
439
|
182
|
1 139
|
651
|
1 496
|
732
|
405
|
701
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
581
|
176
|
214
|
581
|
439
|
182
|
1 139
|
651
|
1 496
|
732
|
405
|
701
|
|
| Cash Equivalents |
31
|
6
|
1
|
0
|
1
|
19
|
0
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
419
|
0
|
40
|
35
|
419
|
419
|
238
|
238
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
2
|
1
|
1
|
1
|
1
|
1
|
7
|
2
|
3
|
8
|
7
|
12
|
10
|
32
|
65
|
92
|
160
|
89
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
1
|
0
|
1
|
0
|
10
|
43
|
78
|
145
|
54
|
|
| Other Receivables |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
7
|
2
|
3
|
7
|
7
|
11
|
10
|
23
|
22
|
14
|
15
|
36
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
6
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
0
|
1
|
3
|
6
|
21
|
43
|
30
|
18
|
0
|
|
| Total Current Assets |
32
|
8
|
2
|
1
|
3
|
21
|
2
|
866
|
178
|
257
|
624
|
866
|
616
|
1 393
|
942
|
1 605
|
855
|
585
|
797
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
2
|
3
|
4
|
6
|
15
|
10
|
42
|
36
|
27
|
18
|
13
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
2
|
3
|
4
|
0
|
15
|
10
|
42
|
36
|
27
|
18
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
0
|
6
|
7
|
8
|
7
|
9
|
11
|
0
|
|
| Intangible Assets |
34
|
37
|
36
|
36
|
38
|
40
|
40
|
33
|
36
|
37
|
34
|
33
|
33
|
31
|
29
|
47
|
136
|
197
|
231
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
126
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
4
|
8
|
40
|
7
|
15
|
19
|
40
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
68
N/A
|
45
-34%
|
38
-15%
|
38
-1%
|
41
+8%
|
66
+61%
|
51
-23%
|
945
+1 760%
|
224
-76%
|
311
+39%
|
680
+119%
|
945
+39%
|
664
-30%
|
1 434
+116%
|
1 013
-29%
|
1 687
+67%
|
1 018
-40%
|
801
-21%
|
1 167
+46%
|
|
| Liabilities | ||||||||||||||||||||
| Accounts Payable |
1
|
1
|
1
|
4
|
1
|
1
|
1
|
4
|
1
|
6
|
4
|
40
|
51
|
27
|
53
|
62
|
87
|
38
|
0
|
|
| Accrued Liabilities |
2
|
0
|
2
|
1
|
2
|
1
|
3
|
31
|
11
|
19
|
38
|
31
|
39
|
66
|
86
|
127
|
134
|
127
|
121
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
3
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
4
|
7
|
7
|
8
|
8
|
145
|
|
| Other Current Liabilities |
0
|
3
|
3
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
2
|
0
|
0
|
18
|
25
|
68
|
92
|
84
|
144
|
|
| Total Current Liabilities |
3
|
4
|
5
|
6
|
6
|
3
|
5
|
72
|
13
|
26
|
44
|
72
|
95
|
114
|
171
|
265
|
321
|
256
|
411
|
|
| Long-Term Debt |
22
|
0
|
8
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
6
|
1
|
28
|
784
|
859
|
1 071
|
789
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
0
|
1
|
6
|
12
|
1
|
76
|
55
|
35
|
5
|
63
|
51
|
|
| Total Liabilities |
25
N/A
|
4
-83%
|
13
+222%
|
6
-58%
|
6
+11%
|
3
-58%
|
5
+96%
|
85
+1 566%
|
13
-85%
|
27
+115%
|
50
+84%
|
85
+71%
|
101
+19%
|
192
+90%
|
255
+33%
|
1 084
+325%
|
1 186
+9%
|
1 390
+17%
|
1 251
-10%
|
|
| Equity | ||||||||||||||||||||
| Common Stock |
19
|
19
|
19
|
39
|
68
|
22
|
22
|
38
|
32
|
35
|
38
|
41
|
41
|
46
|
46
|
55
|
55
|
68
|
0
|
|
| Retained Earnings |
24
|
21
|
6
|
7
|
33
|
41
|
24
|
364
|
76
|
187
|
364
|
581
|
891
|
1 312
|
1 860
|
2 471
|
3 303
|
4 109
|
0
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
947
|
253
|
429
|
947
|
1 401
|
1 413
|
2 509
|
2 573
|
3 022
|
3 083
|
3 451
|
0
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
2
|
6
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
3
|
2
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
168
|
589
|
84
|
|
| Total Equity |
43
N/A
|
41
-6%
|
25
-39%
|
32
+29%
|
35
+8%
|
63
+82%
|
46
-28%
|
860
+1 782%
|
212
-75%
|
284
+34%
|
631
+122%
|
860
+36%
|
563
-35%
|
1 242
+121%
|
758
-39%
|
603
-20%
|
168
N/A
|
590
-251%
|
84
+86%
|
|
| Total Liabilities & Equity |
68
N/A
|
45
-34%
|
38
-15%
|
38
-1%
|
41
+8%
|
66
+61%
|
51
-23%
|
945
+1 760%
|
224
-76%
|
311
+39%
|
680
+119%
|
945
+39%
|
664
-30%
|
1 434
+116%
|
1 013
-29%
|
1 687
+67%
|
1 018
-40%
|
801
-21%
|
1 167
+46%
|
|
| Shares Outstanding | ||||||||||||||||||||
| Common Shares Outstanding |
6
|
6
|
6
|
10
|
15
|
24
|
24
|
40
|
32
|
35
|
38
|
40
|
40
|
44
|
44
|
52
|
53
|
68
|
102
|
|
Switch to:
Switch to:
See Also
Discover More
